The Luxturna treatment, carried out at the Vision Center at the Children’s Hospital Los Angeles (CHLA), replaces the defective gene RPE65 – responsible for producing a protein that makes light receptors work – with a healthy copy made from artificial DNA.
Sign in to continue
Not already a member of the College?
Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
For the very last issue of Optometry in Practice, Professor Jonathan Jackson MCOptom reflects on the past two decades of the journal and its contribution to our learning.